Numinus files a patent application for a “process” that can allow faster, more cost-effective production of psychoactive compounds such as psilocybin.

Mydecine’s novel molecule, MYCO-004 is targeting multiple forms of addiction/substance abuse.

Lysergic acid diethylamide, or LSD, is a drug which produces a variety of cognitive, perceptual and behavioral changes in users.

The newest member of Cybin’s Clinical Advisory Board previously held a senior position with the FDA.

A House subcommittee on Thursday approved a large-scale funding bill that includes provisions protecting banks from being punished for working with marijuana businesses and allowing Washington, D.C. to legalize cannabis sales.

Psychedelic Stock Watch explains why astute investors will put their dollars into both “experiential” and non-psychoactive psychedelic drug R&D.

Field Trip reports Q4 and full-year results for fiscal 2021. Cash position of CAD$111m. Clinic revenues increased by 63% q-o-q to CAD$526,435.

Sometimes biggest is not “best”. Psychedelic Stock Watch offers investors a lot of reasons why thinking SMALLER may be more profitable.

Investors of Mydecine Innovations Group received a pleasant surprise Tuesday morning, drawing coverage from a firm that is making itself known in the psychedelics industry.

Novamind’s new Chief Scientific Officer is a physician with deep knowledge of psychiatry and palliative care, including familiarity with ketamine-assisted psychotherapy.